DRTB-HDT

Current TB treatments are long, complex and often poorly tolerated; moreover, cases of the drug-resistant (rifampicin-resistant (RIF-R)) form of TB magnify this global health threat... In addition to these well-recognized shortcomings, current TB treatments, particularly those for RIF-R TB, leave a majority of cured patients with permanent, clinically significant lung impairment and radiographic evidence of bronchiectasis and fibrosis... The EU-funded DRTB-HDT project will determine if two adjunctive host-directed therapies can prevent the poor outcomes of treatment in cases of RIF-R TB. Patients with RIF-R TB and other risk factors for poor outcome will participate in a randomised, controlled, three-armed multicentre trial.